Compare McCormick & Company, Incorporated (MKC) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Viatris Inc — how do they compare? McCormick & Company, Incorporated trades at $51.5 (market cap $13.90B), while Viatris Inc trades at $16.5 (market cap $18.95B). The key difference: Viatris Inc is the larger of the two by market cap, and McCormick & Company, Incorporated pays the higher dividend (3.73%). Which is the better fit depends on your goals.
| MKC | VTRS | |
|---|---|---|
Market Cap | $13.90B | $18.95B |
Sector | Consumer Staples | Health |
52-Week High | $71.65 | $17.86 |
52-Week Low | $45.60 | $9.49 |
Enterprise Value | $18.50B | $31.07B |
Dividend Yield | 3.73% | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MKC trades at $51.90, down 0.35% with a bearish technical signal. The stock shows strong fundamentals with a low P/E of 8.64, robust 21.91% net margin, and consistent revenue growth to $6.84B in 2025. Recent Q1 2026 earnings beat expectations, while analyst consensus is mixed with 36.67% buy ratings. The pending Unilever merger and upcoming Q3 2026 earnings on October 1, 2026, are key catalysts.
MKC presents a value opportunity with attractive valuation metrics and solid profitability, though technical indicators suggest near-term pressure. The Unilever deal integration and margin expansion potential support long-term growth, but execution risks and competitive pressures remain concerns. Current price sits near the analyst low target of $52.00, offering limited downside protection.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
